INTRODUCTION
============

Intracranial aneurysm (IA) is a complex disease characterized by pathologic dilatations of the cerebral arteries. The prevalence of IA is 2--5% worldwide and approximately 7% in Chinese adults aged 35 to 75 years old.[@B1][@B2] The rupture of an IA leads to subarachnoid hemorrhage (SAH), which is one of the most devastating known neurological conditions.[@B3] Although the pathogenesis of IA has been explored for many years, the mechanisms of its formation, growth, and rupture remain largely unknown. IA treatment mainly relies on invasive neurosurgical clipping or endovascular coiling with a risk of procedural morbidity and mortality.[@B4]

Multiple factors, such as hypertension, smoking, excessive alcohol consumption, increasing age, and female sex, are known to be risk factors for IA.[@B5] Furthermore, the familial occurrence of IA and its association with certain genetic disorders, such as autosomal dominant polycystic kidney disease and Ehlers-Danlos syndrome, suggest a genetic component important to IA formation.[@B6] Upon linkage analysis and candidate gene association studies, several common variants of collagen type I alpha 2 chain (*COL1A2*: rs42524), collagen type III alpha 1 chain (*COL3A1*: rs1800255), heparan sulfate proteoglycan 2 (*HSPG2*: rs3767137), serpin family A member 3 (*SERPINA3*: rs4934), and versican (*VCAN*: rs251124 and rs173686) were found to be associated with IA.[@B7] Further genome-wide association studies (GWAS) and case-control replication analysis identified novel common variants for IA, such as variants near or on endothelin receptor type A (*EDNRA*: rs6841581), histone deacetylase 9 (*HDAC9*: rs6841581), sex determining region Y-box 17 (*SOX17*: rs10958409), RP1 axonemal microtubule associated (*RP1*: rs9298506), CDKN2B antisense RNA 1 (*CDKN2B-AS1*: rs10757278), and RB binding protein 8, endonuclease (*RBBP8*: rs11661542).[@B8][@B9][@B10][@B11] Despite limited effect sizes of the identified variants \[odds ratio (OR) 1.1--1.5\], these results have provided the foundation for future studies.

Notwithstanding, the GWAS and subsequent replication studies were mainly conducted in Dutch, Finnish, Japanese, and Korean populations. While a few studies have explored associations between *EDNRA* and *CDKN2B-AS1* loci and IA in Chinese populations, due to the small sample sizes and limited statistical power, no definite conclusions were reached in regards to whether these loci contribute to IA pathogenesis in the Chinese population or not.[@B12][@B13][@B14][@B15] Thus, the aim of the present study was to investigate whether there are associations between identified loci and IA risk in a Chinese population.

MATERIALS AND METHODS
=====================

Study population
----------------

In cooperation with hospitals in Hunan Province of China, we recruited IA patients from the Department of Neurology and Neurosurgery of Xiangya Hospital and Hunan People\'s Hospital from December 2016 to February 2018. All patients with IA who agreed to participant in this study during the study period were enrolled. The cases were diagnosed by magnetic resonance imaging, computed tomography angiography, or digital subtraction angiography. Individual information and lifestyle data were collected by interview. Control subjects were recruited from the same geographic region who attended a community routine annual health check-up during the same period. The control subjects met the following criteria: 1) no medical history of any vascular diseases, including IA or SAH, and 2) no family history of IA or SAH in first-degree relatives. Peripheral blood samples were obtained from all enrolled individuals. This study was approved by the Medical Ethics Committee of Clinical Pharmacology Institute, Central South University (CTXY-150002-1), and written informed consent was obtained from all participants.

Single nucleotide polymorphism selection and genotyping
-------------------------------------------------------

Based on previous studies, 12 single nucleotide polymorphisms (SNPs) were selected by searching for SNPs in the GWAS that showed significant associations with IA.[@B9][@B10][@B15][@B16][@B17][@B18] Genomic DNA was extracted from peripheral blood leukocytes using TIANamp Blood DNA Extraction Kits (TIANGEN Biotech Co., Ltd., Beijing, China). The DNA samples were stored at −80℃ until ready for use. SNPs were genotyped using the MassARRAY iPlex platform (Agena Bioscience Inc., San Diego, CA, USA). Primers were designed using ASSAY DESIGN SUITE V2.0 based on a SNP locus ([http://agenacx.com](https://www.agenacx.com), Agena Bioscience Inc.) ([Table 1](#T1){ref-type="table"}). The PCR reaction comprised of 1 µL of genomic DNA (20--50 ng) and 4 µL of Multiplex PCR mixture that contained 1.8 µL of dddH~2~O, 0.5 µL of 10× PCR buffer, 0.4 µL of MgCl~2~ (25 mM), 0.1 µL of dNTP (25 mM), 0.2 µL of HotstarTaq (5 U/µL, Agena Bioscience Inc.), and 1 µL of PCR Primer mix. The PCR conditions were as follows: initial denaturing at 95℃ for 2 minutes, followed by 45 cycles of denaturing at 95℃ for 30 seconds, annealing at 56℃ for 30 seconds, and final extension at 72℃ for 60 seconds. The last step was to hold at 25℃ indefinitely. After shrimp alkaline phosphatase reaction, single base extension, and resin desalting reaction, SNP alleles were identified by different masses of the extended prime primers using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. The mass spectrometry peaks were detected using Typer 4.0 software (Agena Bioscience Inc.) and the genotypes of each sample target locus were interpreted based on the mass spectrum peak map. Genotyping was performed by an operator blinded to the sample status (case or control subjects).

Statistical analysis
--------------------

General clinical features of the case and control groups are described as a mean±standard deviation (SD) and were compared using Student\'s t-test for continuous variables. Categorical variables are presented as proportions and were compared using the chi-square test or Fisher\'s exact test. The Hardy-Weinberg equilibrium of control subjects was tested using Stata 11.2 (StataCorp LLC, College Station, TX, USA). Pair-wise linkage disequilibrium (LD) was estimated using Haploview v.4.2 (<https://www.broadinstitute.org/haploview/haploview>).[@B19] Pairwise LD parameters r^2^ and D′ were used as criteria for judging LD.[@B20] If r^2^≥80%, SNPs were considered in strong LD. Meanwhile, if D′=1, SNPs were considered in complete LD. Univariate and multivariate logistic regression analysis were used to estimate ORs and 95% confidence intervals (CI) of each SNP. A *p* value less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 21.0 software (IBM Corp., Armonk, NY, USA).

RESULTS
=======

Characteristics of study population
-----------------------------------

This study included 230 IA patients and 535 normal individuals without known IA or other cerebrovascular diseases. The demographic and clinical characteristics of the patients and controls are summarized in [Table 2](#T2){ref-type="table"}. In short, female sex was predominant in both groups. The mean age of the controls was older than that of the patients, and smokers were more frequent in the control group. There were no significant distribution differences in sex, hypertension, and alcohol consumption status between case and control groups. In the case group, 72.6% individuals had a single aneurysm. The aneurysms were primarily located in the internal carotid artery (47.6%), followed by the middle cerebral artery (18.1%), anterior communicating artery (13%), and other locations.

Hardy-Weinberg equilibrium and linkage disequilibrium analysis
--------------------------------------------------------------

All SNPs showed 100% genotyping call rate, and the risk allele frequencies were more than 10% in the participants. The genotype distributions of all SNPs were in Hardy-Weinberg equilibrium in the healthy controls (*p*\>0.05) ([Table 3](#T3){ref-type="table"}). LD analysis showed that the SNPs of *SOX17* (rs1504749 and rs10958409) and *CDKN2B-AS1* (rs10757272 and rs1333042) were in strong LD (r^2^\>0.8) ([Fig. 1](#F1){ref-type="fig"}). We chose to focus on SNPs rs10958409 and rs10757272.

Associations between candidate loci and IA
------------------------------------------

The genotypes of 12 SNPs and their associations with IA are presented in [Table 3](#T3){ref-type="table"}. SNPs in *CDKN2B-AS1* (especially rs10757272) showed significant associations with IA in univariate logistic regression analysis in different genetic models ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online). These associations between *CDKN2B-AS1* variations and IA remained significant after adjustment for age and smoking in the dominant and additive models ([Table 3](#T3){ref-type="table"}). One SNP in *RP1* (rs9298506) was markedly associated with IA in a recessive model (OR, 3.82; 95% CI, 1.84--7.91). However, another SNP near *RP1* (rs1072737) showed a protective effect on IA in a dominant model (OR, 0.66; 95% CI, 0.46--0.95) both in univariate and multivariate analyses. The above associations were verified in the 208 Chinese Han individuals in the 1000 Genomes Project as additional controls ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online). The SNP near *HDAC9* (rs10230207) showed conflicting results with IA. It was associated with IA in the dominant model when adjusted for age and smoking (OR, 1.42; 95% CI, 1.01--1.99), while this association was not replicated in the additional control ([Table 3](#T3){ref-type="table"}, [Supplementary Tables 1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}, only online). SNPs near *EDNRA* (rs6841581), *SOX17* (rs1504749 and rs10958409), and *RBBP8* (rs11661542) did not show associations with IA in any genetic model, whether adjusted age and smoking or not (all *p*\>0.05).

Comparison of the associations with other studies
-------------------------------------------------

The comparisons of our results with those of other studies are summarized in [Supplementary Table 3](#S3){ref-type="supplementary-material"} (only online). Generally, only *CDKN2B-AS1* loci showed similar associations in Chinese population with those in European and Japanese populations. For the associations of common variants on or near *EDNRA*, *HDAC9*, *SOX17*, *PR1*, and *RBBP8* loci and IA, inconsistent results were observed in different populations.

DISCUSSION
==========

In this study, we investigated associations among 12 SNPs in loci identified in a previous GWAS and the risk of IA in a Chinese population. The results confirmed that genetic variants in *CDKN2B-AS1*, *RP1*, and *HDAC9* loci were significantly associated with the risk of IA in a Chinese population. However, the associations of variants on or near *EDNRA*, *SOX17*, and *RBBP8* loci with IA were not replicated, suggesting that there were both common and specific susceptibility factors in the Chinese population.

*CDKN2B-AS1*, also known as *ANRIL*, is located within the *CDKN2B-CDKN2A* gene cluster at chromosome 9p21.3.[@B17] SNPs on this locus, especially rs10757272, have been identified to be associated with various vascular diseases, including coronary artery diseases, stroke, myocardial infarction, and abdominal aortic aneurysm.[@B21] Multiple studies also found that common variants of this locus significantly increased the risk of IA in European and Japanese populations, indicating that the *CDKN2B-AS1* locus might contain a common genetic risk factor(s) for multiple vascular diseases.[@B10][@B14][@B17][@B18][@B21][@B22][@B23][@B24][@B25] In agreement with the previous findings, we found that five genotyped SNPs (rs1333040, rs10757272, rs1333042, rs10733376, and rs10757278) on or near *CDKN2B-AS1* were significantly associated with IA in a dominant model and that rs10757272 was further associated with IA in an additive model in Chinese population. Although the exact roles of *CDKN2B-AS1* variants and IA risk are not clear, an animal study revealed that targeted deletion of 9p21 risk loci significantly attenuated the expression of two *CDKN2BASs*\' neighboring tumor-suppressor genes (*p15^INK4b^* and *p16^INK4a^*), thereby altering coronary artery disease progression.[@B26] *P15^INK4b^* and *p16^INK4a^* have been found to play roles in regulating cell cycle and promoting vascular remodeling.[@B27] Variants of *CDKN2B-AS1* have been shown to participate in the formation of atherosclerosis by inhibiting the expression of *p15^INK4b^* and *p16^INK4a^*.[@B28] Thus, we speculate that individuals with *CDKN2B-AS1* variants may be prone to IA due to reduced expression of *p15^INK4b^* and *p16^INK4a^*. This should be explored in future experimental studies.

*RP1* is located at chromosome 8q11.23-q12.1. Variants in this gene were reported to affect retinal phenotype.[@B29] Previous GWASs reported that rs1072737 and rs9298506 were near 3′-*SOX17*.[@B10][@B15] However, according to the most recent Genome Reference Consortium human genome build 38 (GRCh38.p12), rs9298506 is located on the intron of *RP1*, and rs1072737 is located 8 kb upstream from *RP1*, but 41 kb downstream from *SOX17*, which is much closer to *RP1*. Therefore, in this study, we classified rs1072737 and rs9298506 into *RP1*. The two SNPs of *RP1* lacked strong LD both in our study and two other populations (East Asian and European) in the 1000 Genomes Project data ([Fig. 1](#F1){ref-type="fig"}, [Supplementary Fig. 1](#S4){ref-type="supplementary-material"}, only online). Thus these SNPs may have different directions of effect on IA. For rs1072737, Foroud, et al.[@B16] found that the G allele of it increased the risk of IA in individuals of European-ancestry in an additive model. However, Hong, et al.[@B30] reported that the G allele of rs1072737 had a protective effect on IA in a Korean population in an allelic model. For rs9298506, Yasuno, et al.[@B10] and Bilguvar, et al.[@B15] reported that the G allele had a protective effect on IA in European and Japanese populations in an additive model. Nevertheless, in this study, we found that rs1072737 showed a protective effect against IA in a dominant model, while rs9298506 showed a risk effect for IA in a recessive model. Furthermore, the same direction effect of associations between these two SNPs and IA were replicated when we further used data from 208 Chinese Han individuals from the 1000 Genome Project as controls ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online). This provided further evidence to support that *RP1* could be a potential susceptibility gene for IA in Chinese. Due to genetic heterogeneity, common variants of *RP1* might affect IA in different genetic models of diverse ethnic populations. Previous functional analysis of *RP1* mainly focused on its role for retinal disease,[@B29] and the full-length nature of variants in *RP1* is still unknown. Accordingly, the mechanisms of *RP1* variants affecting IA need to be further explored.

*HDAC9* is located at chromosome 7p21.1 and plays roles in regulating ox-LDL-induced endothelial cell apoptosis and inflammatory factor expression.[@B31] Previous studies have shown that chromosome 7p21.1 and *HDAC9* genetic variants were associated with ischemic stroke in Chinese Han, European, and Caucasians populations.[@B32][@B33][@B34] In a subsequent GWAS, Foroud, et al.[@B17] found that rs10230207 near *HDAC9* had a risk effect on IA in white and Dutch populations. Consistent with the findings of Foroud\'s study, we found that rs10230207 increased the risk of IA in our Chinese population after adjustment for age and smoking. Given the small effect size of *HDAC9*, the exact association between *HDAC9* and IA might be covered by other environmental factors. A recent study found that there were significantly gene expression differences between *HDAC9* risk allele-positive and negative large vessel atherosclerotic stroke patients, which illustrated that *HDAC9* variants may be associated with peripheral immune, lipid, and clotting systems. [@B35] Whether *HDAC9* variants affect IA in a similar manner with that in large vessel atherosclerotic stroke is still unknown. Exact mechanisms should be studied in the future.

*EDNRA* is located in chromosome 4q31.22-q31.23 and encodes the receptor for endothelin-1, which is a peptide that plays a role in potent and long-lasting vasoconstriction.[@B36] An allele of rs6841581 near *EDNRA* showed a protective effect on IA in European, Japanese, and Korean populations in an additive model.[@B9][@B37] However, in the present study, we found that rs6841581 was not associated with IA in any genetic models of our Chinese population. The result was consistent with a previous study by Liu, et al.[@B12] Given that genetic heterogeneity of IA exists in different populations, rs6841581 near *EDNRA* may be not evoke susceptibility to IA in Chinese.

*SOX17* is located at chromosome 8q and encodes a member of the SRY-related HMG-box family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate.[@B38] Bilguvar, et al.[@B15] reported that rs10958409 near *SOX17* provided a risk effect on IA in a Japanese population in an additive model. However, the association was not able to be replicated in subsequent studies. Hashikata, et al.[@B11] and Yasuno, et al.[@B10] reported that rs10958409 was not associated with IA in an independent Japanese population. In a European population, rs10958409 increased the risk of IA in an additive model,[@B15] while in a Korean population, rs10958409 was not associated with IA in allelic and additive models.[@B30][@B37] Consistent with the result in the Korean population, we did not identify any associations between rs10958409 and IA in different genetic models. The LD structure of *SOX17* (rs1504749 and rs1958409) in Europeans was different with that in East Asian populations ([Supplementary Fig. 1](#S4){ref-type="supplementary-material"}, only online), which illustrated that rs10958409 near *SOX17* might be a specific variant for IA in the European population.

*RBBP8* is located at chromosome 18q11.2 and may be a tumor suppressor.[@B39] Conflicting results have been reported for *RBBP8* variants in relation to IA in previous GWASs. Yasuno, et al.[@B10] reported that an allele of rs11661542 was significantly associated with IA in Europeans. However, the association was not replicated in a Japanese population.[@B14] Hong, et al.[@B37] reported that rs11661542 had no effect on IA in a Korean population. Our results showed that rs11661542 was not associated with IA in Chinese under any genetic model, which was consistent with the findings in Korea and Japan. The conflicting results between European and Asian populations may be due to population heterogeneity. According to the HapMap database, the minor allele frequency of rs11661542 was 0.44 in Europeans, which was higher than that in Asians (Japanese: 0.37; Korean: 0.37; Chinese: 0.38, respectively).[@B10][@B14][@B37]Therefore, differential allele frequencies of rs11661542 might have different influences on IA risk in European and Asian populations.

The limitations of this study should be mentioned. First, due to the invasive examination and relative expensive cost of cerebrovascular disease checkup, definitely IA-free controls were not available, and we used individuals who did not have medical (or family) history of IA and other cerebrovascular diseases as controls. These individuals were recruited from the community who were attending a routine annual health check-up during the same period and were relatively older than the IA cases. This may perturb the association results. However, considering that the individuals in the control group were without IA and that they should also have been healthy 10 years prior, the results could not be perturbed significantly. Additionally, further logistic regression analysis was performed using additional controls (208 Chinese Han individuals from the 1000 Genome Project), and the results mostly consistent with our current findings ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online), illustrating that our results are stable. Second, we did not perform functional studies, and the exact mechanisms of these variants on IA remain unclear. Further experimental studies are needed. Third, in this study, we only considered variants identified in GWAS, and more comprehensive studies need to be considered in future etiology studies. Recently, exome sequencing has been used to identify rare variants in several genes significantly associated with IA risk in familial cases.[@B40] Whether rare variants of these genes are reflective of the susceptibility to sporadic IA needs to be explored.

In conclusion, we confirmed associations between common variants in *CDKN2B-AS1*, *RP1*, and *HDAC9* and IA in a Chinese population. Our study provides information for a better understanding of IA pathogenesis, although further studies are needed to explore the potential mechanisms of theses variants.
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Linkage disequilibriums of *SOX17* (A), *RP1* (B), and *CDKN2B-AS1* (C) in European, Finnish, East Asian, and Japanese populations.

![Linkage disequilibriums of *SOX17* (A), *RP1* (B) and *CDKN2B-AS1* (C) in case, control, and total groups.](ymj-60-651-g001){#F1}

###### The Positions and Primers Designed for the 12 SNPs

![](ymj-60-651-i001)

  SNP (D/d)^\*^     Position^†^                  Length (bp)   Gene                     Primer    Primer sequence
  ----------------- ---------------------------- ------------- ------------------------ --------- ----------------------------
  rs6841581(G/A)    chr4:147480038               113           *EDNRA* (2 kb)^‡^        Forward   5′-ACATTCACTCTTGGATCCCC-3′
  Reverse           5′-TGCTTGGTGTTGAGTGTTAG-3′                                                    
  rs10230207(G/T)   chr7:19571684                124           *HDAC9* (569 kb)^‡^      Forward   5′-GTCTAAAACACACTGTCCCC-3′
  Reverse           5′-ACTGGCTTTCCCAAAGGAAC-3′                                                    
  rs1504749(A/C)    chr8:54398151                121           *SOX17* (60 kb)^‡^       Forward   5′-TGTCCTGCCCTCCGAAAAAG-3′
  Reverse           5′-AGGTCTTGGCTGGTATTAAC-3′                                                    
  rs10958409(G/A)   chr8:54414531                120           *SOX17* (43 kb)^‡^       Forward   5′-GCAGATGGCAGTTAAGGAAG-3′
  Reverse           5′-TAGTGATTGCCCATCAGAGG-3′                                                    
  rs1072737(T/G)    chr8:54501764                129           *RP1* (8 kb)‡            Forward   5′-TTCTTCTTCAGGGACTCCAG-3′
  Reverse           5′-TGTGGCAATGAAAACTACCC-3′                                                    
  rs9298506(A/G)    chr8:54524964                120           *RP1*                    Forward   5′-GACTTAAGGGTGTCTGGAAG-3′
  Reverse           5′-GGAAACAGCAAACAGCCTAC-3′                                                    
  rs1333040(C/T)    chr9:22083405                110           *CDKN2B-AS1*             Forward   5′-TTTGGGAGCCACTGTTGTAG-3′
  Reverse           5′-CATTCAAGAGAGACAGGAGG-3′                                                    
  rs10757272(C/T)   chr9:22088261                109           *CDKN2B-AS1*             Forward   5′-GCTGGGATTATGAAAGGTCG-3′
  Reverse           5′-AATACCACTGACATGGAGAG-3′                                                    
  rs1333042(A/G)    chr9:22103814                123           *CDKN2B-AS1*             Forward   5′-TTTGAGTAGACAGCCAACCC-3′
  Reverse           5′-TTCAATAGCCAGAAAACCCC-3′                                                    
  rs10733376(G/C)   chr9:22114470                118           *CDKN2B-AS1*             Forward   5′-CTTTGCCTTCCTCTCCTTTC-3′
  Reverse           5′-ATTCGCCGAGGTAAACCTTG-3′                                                    
  rs10757278(A/G)   chr9:22124478                90            *CDKN2B-AS1* (3 kb)^‡^   Forward   5′-ACTCTGTCTTGATTCTGCAT-3′
  Reverse           5′-AGTTGGAACTGAACTGAGGC-3′                                                    
  rs11661542(C/A)   chr18:22643732               115           *RBBP8* (270 kb)^‡^      Forward   5′-AGCTGGACCATGCCATTGTG-3′
  Reverse           5′-ACCCACAACAATTAGTTCCC-3′                                                    

SNP, single nucleotide polymorphism; kb, kilobase.

^\*^Allele D indicates wild-type alleles; d, risk alleles, ^†^The position in Genome Reference Consortium Human genome build 38.p12 (GRCh38.p12), ^‡^SNP near the gene (distance).

###### Demographic and Clinical Characteristics of the Study Participants

![](ymj-60-651-i002)

  Variables                              Case (n=230)   Control (n=535)   *p* value
  -------------------------------------- -------------- ----------------- -----------
  Mean age±SD (yr)                       57.0±10.7      64.7±10.9         0.000
  Female, n (%)                          142 (61.7)     340 (63.6)        0.634
  Hypertension, n (%)                    128 (55.7)     296 (55.3)        0.934
  Smoking, n (%)                         45 (19.6)      147 (27.5)        0.021
  Alcohol consumption, n (%)             36 (15.7)      108 (20.2)        0.141
  Single intracranial aneurysm, n (%)    167 (72.6)     \-                
  Site of intracranial aneurysm, n (%)                                    
   Internal carotid artery               150 (47.6)     \-                
   Middle cerebral artery                57 (18.1)      \-                
   Anterior communicating artery         41 (13.0)      \-                
   Anterior cerebral artery              19 (6.0)       \-                
   Posterior communicating artery        15 (4.8)       \-                
   Vertebral artery                      9 (2.9)        \-                
   Basilar artery                        8 (2.5)        \-                
   Posterior cerebral artery             4 (1.3)        \-                
   Other                                 12 (3.8)       \-                

SD, standard deviation.

###### Multivariate Logistic Regression Analysis of Associations among the 12 SNPs and Risk of Intracranial Aneurysm in a Chinese Population

![](ymj-60-651-i003)

  SNP          Gene           Genotype^\*^   *p*^†^ HWE    Dominant model   Recessive model     Additive model                                                   
  ------------ -------------- -------------- ------------- ---------------- ------------------- ---------------- ------------------- ------- ------------------- -------
  rs6841581    *EDNRA*        142/78/10      298/202/35    0.922            0.82 (0.59--1.14)   0.236            0.66 (0.30--1.44)   0.295   0.82 (0.62--1.09)   0.168
  rs10230207   *HDAC9*        142/83/5       369/149/17    0.680            1.42 (1.01--1.99)   0.046            0.58 (0.19--1.76)   0.334   1.25 (0.93--1.69)   0.146
  rs1504749    *SOX17*        93/117/20      257/223/55    0.521            1.28 (0.92--1.78)   0.142            0.61 (0.34--1.11)   0.106   1.05 (0.82--1.35)   0.699
  rs10958409   *SOX17*        112/101/17     277/211/47    0.454            1.06 (0.77--1.47)   0.728            0.56 (0.29--1.08)   0.084   0.94 (0.73--1.21)   0.634
  rs1072737    *RP1*          168/55/7       348/172/15    0.251            0.66 (0.46--0.95)   0.024            1.15 (0.45--2.96)   0.771   0.74 (0.54--1.01)   0.060
  rs9298506    *RP1*          146/65/19      346/174/15    0.213            1.08 (0.77--1.51)   0.671            3.82 (1.84--7.91)   0.000   1.28 (0.97--1.69)   0.087
  rs1333040    *CDKN2B-AS1*   7/97/126       48/217/270    0.643            3.44 (1.44--8.20)   0.005            1.14 (0.83--1.59)   0.419   1.29 (0.98--1.69)   0.068
  rs10757272   *CDKN2B-AS1*   10/93/127      60/228/247    0.502            2.99 (1.44--6.24)   0.003            1.34 (0.96--1.86)   0.082   1.43 (1.10--1.86)   0.008
  rs1333042    *CDKN2B-AS1*   10/100/120     61/224/250    0.318            3.03 (1.46--6.31)   0.003            1.17 (0.85--1.63)   0.338   1.32 (1.02--1.71)   0.037
  rs10733376   *CDKN2B-AS1*   14/125/91      72/257/206    0.562            2.89 (1.52--5.49)   0.001            1.02 (0.73--1.42)   0.922   1.24 (0.96--1.60)   0.096
  rs10757278   *CDKN2B-AS1*   36/126/68      122/280/133   0.275            1.61 (1.05--2.49)   0.030            1.20 (0.84--1.73)   0.317   1.27 (0.99--1.61)   0.054
  rs11661542   *RBBP8*        68/108/54      146/276/113   0.409            0.86 (0.60--1.23)   0.394            1.08 (0.73--1.59)   0.713   0.96 (0.76--1.21)   0.744

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

^\*^Genotype presented as wild type/heterozygous/homozygous, ^†^Hardy-Weinberg equilibrium (HWE) *p* value for the control group.

[^1]: ^\*^Bingyang Li and Chongyu Hu contributed equally to this work.
